IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

DUMAS, Jacques, et al.

Serial No.: 09/838,286

Group Art Unit: 1614

Filed: 4/20/01

Examiner: William R.A. Jarvis

For: HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.56, 1.97 and 1.98

Assistant Commissioner for Patents Washington, D. C. 20231

Sir:

Applicant(s) hereby disclose the information listed in the attached form PTO-1449.

No fee is required in that this IDS is submitted with an RCE.

Copies of the search reports and notices of references cited have been provided as well as copies of the claims in the copending applications identified below. Copies of the claims have also been provided on the accompanying compact disc.

A copy of the Examination Report in the corresponding International Application has been provided.

Pursuant to 37 CFR $\S1.97$ and $\S1.98$, Applicant identifies the following related copending applications.

Title: Inhibition of RAF Kinase Activity Using Aryl Ureas

Inventor(s): Jill Wood et al.

Filed January 8, 2001, Serial No. 09/755,060

Status: Published

Claims pending as of 6/23/03 attached

Title: RAF Kinase Inhibitors Inventor(s): Jill Wood et al.

Filed May 21, 1998, Serial No. PCT/US98/10376

No U.S. National Phase

Title: Inhibition of p38 Kinase Activity by Aryl Ureas

Inventor(s): Gerald Ranges et al.

Filed September 7, 2001, Serial No. 09/947,761

Claims pending as of 6/23/03 attached

Title: Inhibition of p38 Kinase by Aryl Ureas

Inventor(s): Gerald Ranges et al.

Filed May 21, 1998, Serial No. PCT/US98/10375

No U.S. National Phase

Title: Inhibition of RAF Kinase Using Symmetrical and

Unsymmetrical Substituted Diphenyl Ureas Inventor(s): Scott Miller et al.

Filed December 22, 1998, Serial No. 09/776,936

Claims pending as of 6/23/03 attached

Title: Inhibition of RAF Kinase Using Symmetrical and

Unsymmetrical

Substituted Diphenyl Ureas Inventor(s): William Scott et al.

Filed December 22, 1998, PCT/US98/26081

No U.S. National Phase

Title: Inhibition of RAF Kinase Using Substituted Heterocyclic Ureas

Inventor(s): Jacques Dumas et al. Filed: August 18, 2000, Serial No. 09/640,780 Claims pending as of 6/23/03 attached

Title: Inhibition of RAF Kinase Using Substituted Heterocyclic Ureas

Inventor(s): Jacques Dumas et al.

Filed December 22, 1998, PCT/US98/26078

No U.S. National Phase

Title: Inhibition of RAF Kinase Using Arvl and Heteroarvl Substituted

Heterocyclic Ureas

Inventor(s): William Scott et al.

Filed December 27, 1998, Serial No. 09/472,232

Claims pending as of 6/23/03 attached

Title: Inhibition of RAF Kinase Using Aryl and Heteroaryl Substituted

Heterocyclic Ureas

Inventor(s): Jacques Dumas et al.

Filed December 22, 1998, PCT/US98/26082

No. U.S. National Phase

Title: Inhibition of P38 Kinase Activity Using Symmetrical and

BAYER-14

Unsymmetrical Diphenyl Ureas Inventor(s): Scott Miller et al. Filed February 1, 2002, Serial No. 10/060,396 Claims pending as of 6/23/03 attached

Title: Inhibition of p38 Kinase Using Symmetrical and Unsymmetrical

Diphenyl Ureas

Inventor(s): Scott Miller et al.

Filed: December 22, 1998, PCT/US98/27265

No U.S. National Phase

Title: Inhibition of P38 Kinase Using Substituted Heterocyclic Ureas

Inventor(s): Jacques Dumas et al.

Filed December 10, 1999, Serial No. 09/458,014

Claims pending as of 6/23/03 attached

Title: Inhibition of p38 Kinase Activity Using Substituted Heterocyclic

Ureas

Inventor(s): Jacques Dumas et al.

Filed December 22, 1998, PCT/US98/26080

No U.S. National Phase

Title: Inhibition of p38 Kinase Activity Using Arvl and Heteroarvl

Substituted Heterocyclic Ureas

Inventor(s): Jacques Dumas et al.

Filed December 22, 1998, Serial No. 09/776,935

Claims pending as of 6/23/03 attached

Title: Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl

Substituted Heterocyclic Ureas

Inventor(s): Jacques Dumas et al.

Filed: December 22, 1998, PCT/US98/26079

No U.S. National Phase

Title: Inhibition of RAF Kinase Quinolinyl, Isoquinolinyl or Pyridyl

Ureas

Inventor: Jacques Dumas et al.

Filed April 19, 2002, Serial No. 10/125,369 Claims pending as of 6/23/03 attached

Title: Inhibition of RAF Kinase Quinolinyl, Isoquinolinyl or Pyridyl

Ureas

Inventor: Jacques Dumas et al.

Filed April 19, 2002, Serial No. PCT/US02/12066

No U.S. National Phase

Title: Heteroaryl Ureas Containing Nitrogen Hetero-Atoms As p38

Kinase Inhibitors

Inventor: Jacques Dumas et al.

Filed April 20, 2001, Serial No. 09/838,286 Claims pending as of 6/23/03 attached

Title: Heteroaryl Ureas Containing Nitrogen Hetero-Atoms As p38

Kinase Inhibitors

Inventor: Jacques Dumas et al.

Filed April 18, 2002, Serial No. PCT/US02/12064

No U.S. National Phase

Title: ω-Carboxyaryl Substituted Diphenyl Ureas As RAF Kinase

Inhibitors Inventor: Bernd Riedl et al.

Filed: September 10, 2001, Serial No. 09/948,915

Claims pending as of 6/23/03 attached

Title: ω -Carboxyaryl Substituted Diphenyl Ureas As RAF Kinase

Inhibitors

Inventor: Bernd Riedl et al.

Filed: January 12, 2001, Serial No. PCT/US00/00648

National Phase Serial No. 09/889,227 (pending as of 6/23/03)

Title: Inhibition of Raf Kinase Using Quinolinyl, Isoquinolinyl and

Pyridinyl Ureas

Inventor: Jacques Dumas et al.

Filed February 7, 2001, Serial No. 09/777,920

Claims pending as of 6/23/03 attached

Title: Inhibition of Raf Kinase Using Quinolinyl, Isoquinolinyl

and Pyridinyl Ureas

Inventor: Jacques Dumas et al.

Filed: January 7, 2002, Serial No. PCT/US02/03361

No U.S. National Phase

Title: Method and/or Process for Preparing w-Carboxyaryl Substituted

Diphenyl Ureas as raf Kinase Inhibitors

Filed February 11, 2002, Serial No. 10/071,248

Claims pending as of 6/23/03 attached

Title: Omega-Carboxy Aryl Substituted Diphenyl Ureas as p38 Kinase

Inhibitors

Inventor: Bernd Riedl et al. Filed March 4, 2002, Serial No.10/086,417 Claims pending as of 6/23/03 attached

Title: Aryl Ureas With Angiogenisis Inhibiting Activity Inventor: Jacques Dumas, et. al. Filed February 11, 2003, Serial No.10/361,858 Claims pending as of 6/23/03 attached

Title: ω-Carboxyaryl Substituted Diphenyl Ureas as RAF Kinase Inhibitors Inventor(s): Riedl et al. Filed November 27, 2001, Serial No. 09/993,647 Claims pending as of 6/23/03 attached

Title: ω-Carboxyaryl Substituted Diphenyl Ureas As RAF Kinase Inhibitors Inventor(s): Riedl et al. Filed January 11, 2002, Serial No. 10/242,226 Claims pending as of 6/23/03 attached

Title: ω-Carboxyaryl Substituted Diphenyl Ureas As RAF Kinase Inhibitors Inventor: Riedl et al. Filed: July 19, 2001, Serial No. 09/907,970 Claims pending as of 6/23/03 attached

Title: o-Carboxyaryl Substituted Diphenyl Ureas As RAF Kinase Inhibitors Inventor: Riedl et al. Filed: October 30, 2002, Serial No. 10/283,248 Claims pending as of 6/23/03 attached

Title: Aryl Urea Compounds In Combination with Other Cytostatic or Cytotoxic Agents ForTreating Human Cancers Inventor: Carter et al Filed December 3, 2002, S.N. 10/308,187
Claims pending as of 6/23/03 attached

Title: Aryl Ureas As Kinase Inhibitors Inventor: Jacques Dumas. Filed: February, 11, 2003, S.N. 10/361,859 Claims pending as of 6/23/03 attached

Title:Aryl Ureas With raf Kinase and Angiogenisis Inhibiting Activity Inventor: Jaques Dumas Filed: February, 11, 2003, S.N. 10/361,844 Claims pending as of 6/23/03 attached

Title:Pyridine, Quinoline and Isoquinoline N-oxides as Kinase

5

BAYER-1-4

Inhibitors
Inventor: Jacques Dumas
Filed: February, 11, 2003, S.N. 10/361,850
Claims pending as of 6/23/03 attached

FEES

No fee is believed due.

DEPOSIT ACCOUNT

The Commissioner is hereby authorized to charge any further fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402.

Respectfully submitted,

Richard J. Traverso (Reg. No. 30,595) Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: BAYER 25A

Date: July 9, 2003

RJT:jqs

K:\Bayer\14\IDS 7-9-03.dot

plus sign (+) inside this box → | +| +|
Under the Paperwork Reduction Act of 1995, he selected to the 1995 Act of 1995, he selected to the 1995 Act of 1995, he selected to 1995 Act of 1995 Act Please type a plus sign (+) inside this box Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Asked to respond to a collection of information unless it contains a valid OMB control number

JUL 0 9 2003

Substitute for form 1449A/PTO INFORMATION DISCLOSURE

STATEMENT BY APPLICANT (use as many sheets as necessary)

Complete if Known Application Number 09/838.286 Filing Date 4-20-01 First Named Inventor DUMAS, Jacques, et. al. 1614 Group Art Unit Examiner Name William R. A. Jarvis Attorney Docket Number BAYER-14

Sheet

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
		Dumas, J., "CAS Structure," May 6, 1997, pages 1-29	
		Scott,Bill, "Substructure (Patent Families)", August 11, 1997, pages 1-19.	
		Scott, Bill, "Substructure #2", November 25, 1997, pages 1-3.	
		"Beilstein number" Collection, 28 pages (1997)	
		"Beitstein Collection", 4 pages (1997)	
		Scott, Bill, "Substructure Search", December 2, 1997, pages 1-51.	
		Substructure Search, pages 1-30. (1997)	
		Derwent World Patents Index Search, pages 20-26. (1997)	
		A "Notice of References Cited" from the USPTO for U.S. application 08/995,749.	
		A "Notice of References Cited" from the USPTO for U.S. application 09/083,399.	
		A "Notice of References Cited" from the USPTO for U.S. application 09/425,228.	
		A "Notice of References Cited" from the USPTO for U.S. application 09/425,229.	
		A "Notice of References Cited" from the USPTO for U.S. application 09/458,015.	
		A "Notice of References Cited" from the USPTO for U.S. application 09/472,232.	
		A "Notice of References Cited" from the USPTO for U.S. application 09/472,232.	
		A "Notice of References Cited" from the USPTO for U.S. application 09/773,604.	
		A "Notice of References Cited" from the USPTO for U.S. application 09/773,659.	
		A "Notice of References Cited" from the USPTO for U.S. application 09/773,672.	
		A "Notice of References Cited" from the USPTO for U.S. application 09/773,675.	

Signature Considered	Examiner Signature		Date Considered	
----------------------	-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark — Office, Washington, DC 20231. Do NOT SEND PEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

PFIOSBORA (or Approved for use through 10/31/2022, CMB 061-303).

Approved for use through 10/31/2022, CMB 061-3031.

Under the Pigenwork Reduction Act of 1985, no persons interfaced in septond to collection of fermation where a Property of the Pigenwork Reduction Act of 1985, no persons interface and approved to collection of fermation where a Property of the Pigenwork Reduction Act of 1985, no persons interface and approved to collection of fermation where a Property of the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork Reduction Act of 1985, no persons interface and approved to the Pigenwork R

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complet if Known 09/838.286 Application Number Filing Date April 20, 2001 First Named Inventor Jacques DUMAS et al. 1614 Group Art Unit Examiner Name William R.A. Jarvis

(use as many sheets as necessary) Sheet 2

of 3 Attorney Docket Number BAYER 14

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
	AM	A "Notice of References Cited" from the USPTO for U.S. application 09/776,935.		
	AN	A "Notice of References Cited" from the USPTO for U.S. application 09/776,936.		
	AO	A "Notice of References Cited" from the USPTO for U.S. application 09/777,920.		
	ΑP	A "Notice of References Cited" from the USPTO for U.S. application 09/948,915.		
	AQ	A "Notice of References Cited" from the USPTO for U.S. application 10/042,226.		
	AR	A "Notice of References Cited" from the EPO fro European application EP 98/963809.		
	AS	Supplemental search report from the EPO for European application EP 98/963810.		
	АТ	Supplemental search report from the EPO for European application EP 98/965981.		
	AU	Supplemental search report from the EPO for European application EP 00/903239.		
	ВА	International search report for International Application No. PCT/US98/10375.		
	ВВ	International search report for International Application No. PCT/US98/10376.		

Examiner Signature		Date Considered	
	<u> </u>		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RJT/lyb

K:\Bayer\25A\refs cited ids 10-29-02.dot

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burdan Nov Stebenset: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any commentation the encount of time you are required to complete this form should be sent to the Chel information Officer, U.S. Patient and Trademark Office, Weshington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patient, Washington, DC 20231.

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to respond to a collection of information unless it contains a valid OMB control number

	Under the Paperwork Reduction Act of 1995, no persons are re-	required to respond to a conscitor or thornestor or local troop and or the			
	Substitute for form 1449A/PTO		Complete if Known	_	
		Application Number	09/838,286		
	INFORMATION DISCLOSURE	Filing Date	April 20, 2001		
	STATEMENT BY APPLICANT	First Named Inventor	Jacques DUMAS et al.		
		Group Art Unit	1614		
	(use as many sheets as necessary)	Examiner Name	William R.A. Jarvis	Ī	
$\overline{}$	Sheet 3 of 3	Attorney Docket Number	BAYER 14	7	

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title ten (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-is Initials * No. In the control of the control o		T ²		
	вс	International search report for International Application No. PCT/US98/26078.		
	BD	International search report for International Application No. PCT/US98/26079.		
	BE	International search report for International Application No. PCT/US98/26080.		
	BF	International search report for International Application No. PCT/US98/26081.		
	BG	International search report for International Application No. PCT/US98/26082.		
-	вн	International search report for International Application No. PCT/US98/24265.		
	Ві	International search report for International Application No. PCT/US0000648.		
	BJ	International search report for International Application No. PCT/US00/00768.		
	вк	International search report for International Application No. PCT/US02/12064.		
	BL	International search report for International Application No. PCT/US02/12068.		
	ВМ	International search report for International Application No. PCT/US/26081.		

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RJT/lvb K:\Bayer\25A\refs cited lds 10-29-02.dot

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.